Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients
Pakistan Journal of Pharmaceutical Sciences. 2016; 29 (6 Supp.): 2385-2389
Dans Anglais
| IMEMR
| ID: emr-185043
ABSTRACT
Obesity, dyslipidemia and hypertension are major risk factors for cardiovascular disease and its associated complications. To evaluate the beneficial effects of sitagliptin and metformin in non-diabetic dyslipidemic and hypertensive patients. A prospective randomized clinical trial was conducted on 70 newly diagnosed dyslipidemic patients with BMI >/= 25 and blood pressure >/= 130/80 at outpatient clinic of medical unit-1 of sheikh medical college /hospital Rahim Yar Khan. They were divided in to three groups each containing 35 patients; First group served as a healthy control while second and third study groups were given tablet sitagliptin 50mg and tab metformin 850mg respectively twice a day for twelve weeks. After three months treatment with sitagliptin and metformin there was significant reduction in body weight [Sitagliptin 6.5% vs Metformin 7.65%] and BMI [Sitagliptin 2.2% vs Metformin 2.8%] with p = 0.05. Metformin caused a significant reduction in blood pressure with p = 0.05 [i.e. SBP 9.9% and DBP 6.4%] while sitagliptin caused a highly significant p = 0.01 reduction in blood pressure [i.e. SBP 15.8% and DBP 12.2%]. There was significant improvement in lipid profile with sitagliptin p = 0.05. The percent reduction in value of TC, TG and LDL-C was 20.2%, 13.8% and 23.7% while HDL-C value was increased 11.2% respectively. There was highly significant improvement in lipid profile with metformin p = 0.01. The percent reduction in value of TC, TG and LDL-C was 27.8%, 28.2% and 40.4% while HDL-C value was increased 16.8% respectively. Both drugs improve cardiometabolic risk factors independently in non-diabetic patients
Recherche sur Google
Indice:
Méditerranée orientale
Type d'étude:
Essai clinique contrôlé
langue:
Anglais
Texte intégral:
Pak. J. Pharm. Sci.
Année:
2016
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS